Reference Center for Biological Markers of Dementia (BIODEM), Laboratory of Neurochemistry and Behavior, Institute Born-Bunge, University of Antwerp, Antwerp, Belgium.
Innogenetics NV (Miraca/Fujirebio Group), Ghent, Belgium.
Alzheimers Dement. 2014 Oct;10(5 Suppl):S290-8. doi: 10.1016/j.jalz.2013.10.004. Epub 2014 Jan 15.
Given the difficult clinical differential diagnosis between Alzheimer's disease (AD) and dementia with Lewy bodies (DLB), growing interest resulted in research on α-synuclein as a potential cerebrospinal fluid biomarker (CSF) for synucleinopathies.
CSF α-synuclein-140 concentrations were determined by a prototype xMAP™ bead-based assay (Innogenetics NV, Belgium). In addition, CSF amyloid β1-42 (Aβ1-42), total tau (T-tau), and phosphorylated tau (P-tau181P) levels were determined.
CSF α-synuclein levels were higher in AD patients as compared with cognitively healthy controls (P=.019) and patients with synucleinopathies (P<.001). CSF α-synuclein levels were correlated with T-tau (P<.001) and P-tau181P (P<.001) levels in autopsy-confirmed AD patients. A diagnostic algorithm using α-synuclein and P-tau181P discriminated neuropathologically confirmed AD from DLB patients, resulting in sensitivity and specificity values of 85% and 81%, respectively.
Because CSF α-synuclein levels were significantly higher in AD as compared with synucleinopathies, α-synuclein might have a value as a biomarker for differential dementia diagnosis.
鉴于阿尔茨海默病（AD）与路易体痴呆（DLB）之间临床鉴别诊断困难，因此人们对α-突触核蛋白作为潜在的突触核蛋白病脑脊液生物标志物（CSF）的研究兴趣日益浓厚。
采用 Innogenetics NV（比利时）的 xMAP™ 珠基分析测定法（ prototype xMAP™ bead-based assay）测定 CSFα-突触核蛋白-140 浓度。此外，还测定了 CSF 淀粉样蛋白β1-42（Aβ1-42）、总tau（T-tau）和磷酸化 tau（P-tau181P）水平。
与认知健康对照者（P=.019）和其他突触核蛋白病患者（P<.001）相比，AD 患者的 CSFα-突触核蛋白水平更高。CSFα-突触核蛋白水平与尸检确诊 AD 患者的 T-tau（P<.001）和 P-tau181P（P<.001）水平相关。采用α-突触核蛋白和 P-tau181P 的诊断算法可区分经神经病理学确诊的 AD 与 DLB 患者，其敏感性和特异性值分别为 85%和 81%。
由于 AD 患者的 CSFα-突触核蛋白水平明显高于突触核蛋白病患者，因此α-突触核蛋白可能作为鉴别性痴呆诊断的生物标志物具有一定价值。
